The wider-than-expected loss and higher cash burn reflect the ramp-up of the pivotal trial. The key catalyst is the FORTIFI-HN01 interim analysis in mid-2027. Monitor enrollment updates and any early efficacy signals from the FORTIFI-FLEX dosing study.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $9.98entry
- T+1 · 7d ago +2.00%α +2.37% · $10.18
- T+5 · 16h ago −2.30%α −0.61% · $9.75
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bicara Therapeutics reported Q3 2026 net loss of $71.2M ($1.04 per share), wider than the $36.3M loss a year ago, as R&D and G&A costs rose sharply to support the pivotal FORTIFI-HN01 trial. The company achieved substantial enrollment in the trial and expects interim topline data in mid-2027. Cash of $442.3M is expected to fund operations into H1 2029.
Key Financial Metrics
Key Facts
- Net loss of $71.2M in Q3 2026 vs $36.3M in Q3 2025
- EPS of -$1.04 vs consensus -$0.86 (miss of 20.9%)
- Revenue $0 (pre-revenue clinical-stage company)
- Cash, cash equivalents and marketable securities $442.3M as of Sep 30, 2026
- Cash runway into first half of 2029
- Substantial enrollment achieved in FORTIFI-HN01 pivotal trial; interim data expected mid-2027
- R&D expenses $56.5M in Q3 2026 vs $33.0M in Q3 2025
- G&A expenses $19.2M in Q3 2026 vs $7.7M in Q3 2025
Financial Impact
Net loss widened to $71.2M from $36.3M; EPS -$1.04 vs consensus -$0.86; cash burn increased as trial enrollment accelerated
Risk Factors
- Clinical-stage company with no approved products or revenue
- EPS miss of 20.9% vs consensus
- Rising R&D and G&A costs may pressure cash runway if trial timelines extend
- Interim analysis results not expected until mid-2027, leaving a long period without catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398297 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers